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mendations reduced 57% the probability of uncontrolled blood pressure. Having
uncontrolled blood pressure at the baseline stage increased the probability of lack
of control in 166%, and per each unit of increase in body mass index the lack of
control increased 7%. CONCLUSIONS: CME intervention improved the medical de-
cision-making process to manage hypertension, thus increasing the probability of
hypertensive patients to have blood pressure under control.
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OBJECTIVES: The objective of the study was to examine rates of depression treat-
ment and variations in depression treatment by demographic, socioeconomic, ac-
cess to care, health status, and life-style characteristics among women with
hypertension. METHODS: The study design was cross-sectional, using data on
from 2006 and 2007 Medical Expenditure Panel Survey (MEPS), large-scale surveys
of families and individuals to provide nationally representative estimates of health
care use and expenditures. The study included 1304women aged 22 and older with
hypertension and depression, identified from MEPS medical condition files. Anti-
depressantswere identified fromprescription drug reports and psychotherapywas
identified from outpatient visits files. Depression treatment patterns by demo-
graphic, socioeconomic, healthcare access and health status were analyzed using
chi-square tests, logistic regression and multinomial logistic regressions. All anal-
ysis accounted for the complex design of the MEPS using SAS 9.2. RESULTS: In our
study sample, 23.9% had no depression treatment, 56.8% had antidepressant use
only, and 19.3% had psychotherapy with or without antidepressants. Among
womenwith hypertension and depression, African Americans (AOR 0.47), Latina
(AOR 0.46), and uninsured (AOR 0.39) were significantly less likely to report any
treatment for depression compared to Whites and those with private insurance.
Compared to no treatment, psychotherapy with or without antidepressants was
less likely among those with less than high school education and more likely
among women reporting fair/poor mental health. CONCLUSIONS: Nearly one-
quarter of women with hypertension did not have treatment for depression. Dis-
parities in depression treatment by race/ethnicity, health insurance, and education
status were noted. Further studies need to explore reasons for not receiving de-
pression treatment and whether such lack of treatment for depression is associ-
ated with poor health outcomes in these women.
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OBJECTIVES: To evaluate the effect of insurance status on the use of ARBs and ACE
inhibitors among post-Myocardial Infarction (MI) patients. METHODS: The 2007
full-year consolidated data from the Medical Expenditure Panel Survey (MEPS),
nationally representative survey, was used and linked with the prescribed medi-
cine data. A cross-sectional survey data analysiswas performed to evaluate the use
of ARBs and ACE inhibitors in patients diagnosed with Myocardial Infarction (MI)
and its relationship with patients’ insurance status. The outcome measures in-
cluded the binary variables of ACE inhibitor and ARB usage. A total of 464 post-MI
patients were included in the analyses by conducting multivariate logistic regres-
sion, controlling for socio-economic and demographic variables. RESULTS: Out of
464 patients with MI, 67 (14.44%) used only ARBs, 244 (52.59%) used only ACE inhib-
itors, 15 (3.23%) used both drugs, and 138 (29.74%) used neither ARBs nor ACE
inhibitors. Patients with Medicare coverage only and patients without insurance
were less likely to use ARBs, compared to patients with private insurance (adjusted
OR 0.26, p0.018; adjusted OR 0.03, p0.064, respectively). There was no significant
difference between health insurance status and use of ACE inhibitors. Further-
more, health insurance status was not significantly different among patients who
used neither ARBs nor ACE inhibitors. AmongMI patients who used both ARBs and
ACE inhibitors, patients with Medicare coverage only were less likely to use both
drugs (adjusted OR 0.02, p0.001), relative to patients with private insurance. Ad-
ditionally, patients with educational attainment of higher than college degrees
were more likely to use both drugs than those who did not finish college degrees
(adjusted OR 19.61, p0.042). CONCLUSIONS: Health insurance significantly af-
fected the usage of more expensive ARBs but not less expensive ACE inhibitors.
Policy makers need to be aware of the moral hazard arising from the insurance
coverage in drug use.
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OBJECTIVES: To assess demographic and clinical factors associated with statin
selection among elderly patients. METHODS: A retrospective cohort study was
conducted to examine predictors of statin selection among patients aged 365 years,
who initiated pravastatin (PS) vs. simvastatin (SS), atorvastatin (AS), or rosuvasta-
tin (RS) between 1/1/2007 and 12/31/2007. Index statin use was defined as the first
statin claim following at least 90 days of no statin access. Multiple logistic regres-
sion models were employed to assess predictive factors of PS initiation versus
other statin initiations. RESULTS:Of 96,450 statin users identified, there were 8,165
PS initiators, 38,099 AS initiators, 11,320 RS initiators, and 38,866 SS initiators.
Compared to other statin users, a higher percentage of PS initiatorswere aged75-85
(PS: 42.3%, SS: 41.0%, AS: 41.1%, RS: 38.0%, P0.01) andmore likely to be female (PS:
56.6%, SS: 51.3%, AS: 51.5%, RS: 55.7%, P0.01). PS initiatorsweremore likely to have
atrial fibrillation (PS: 10.0%, SS: 9.4%, AS: 9.6%, RS: 8.6%, P0.01) and take warfarin
(PS: 11.7%, SS: 9.8%, AS: 10.4%, RS: 9.9%, P0.01) and triazoles (PS: 3.1%, SS: 2.4%, AS:
2.6%, RS: 2.8%, P0.01) in the baseline period. A higher percentage of PS initiators
took more than 3 unique medications 90-day prior to the index date (PS: 85.4%, SS:
81.8%, AS: 83.0%, RS: 83.9%, P0.01). After controlling for demographic and clinical
characteristics, use ofwarfarinwas associatedwith initiating PS comparedwith SS,
AS, and RS. Other predictors of PS initiation included prior history of atrial fibrilla-
tion, HIV infection and use of calcium channel blockers, ezetimibe, and fenofi-
brates over the 1-year pre-index period compared with AS and SS. CONCLUSIONS:
Patient profiles were different among PS users compared to other statin users.
Selected comorbidities and prior use of certain medications were significant pre-
dictors of PS initiation among a cohort of Medicare patients.
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OBJECTIVES: In 2008, therewere currently 6 statins available in theU.S.market and
more than 193million statin prescriptionswerewritten.We sought to examine the
patterns of statin use among privately insured commercial and Medicare patients
in the U.S. METHODS: A retrospective analysis was performed using MarketScan
Commercial and Medicare data from Jan. 2008 to Dec. 2008. Two cohorts were
created: 1) the commercial cohort (CC) and 2) the Medicare cohort (MC). Statin
scripts of minimum 30 day supply were extracted from the pharmacy claims data
and individual demographic and clinical information were linked from their med-
ical and administrative records. Prescription patternswere examined and analyses
by age and genderwere performed.RESULTS:Therewere 18million and 9.8million
statin prescriptions filled by the CC and MC, respectively. In both cohorts, simva-
statin accounted for the largest share of statin prescriptions (MC: 44.1%; CC: 44.0%),
followed by atorvastatin (MC: 31.6%; CC: 31.1%), rosuvastatin (MC: 7.8%; CC: 11.2%),
pravastatin (MC: 8.1%; CC: 6.5%), lovastatin (MC: 7.4%; CC: 6.6%) and fluvastatin
(MC: 0.9%; CC: 0.6%). The majority of statin prescriptions were for generics (MC:
59.6%; CC: 57.1%).The average annual number of statin prescription per user was
9.3 for the MC and 7.6 for the CC. In the CC, 58.1% of prescriptions were filled by
male, while 50.4% of prescriptions were filled by male in the MC. Diabetic patients
accounted for 35.2% of prescriptions in the MC, and 26.8% in the CC. Milligram
dosing distributions (mean; median; mode) were for simvastatin (MC:32.1; 20;20
CC:32.9;20;40); atorvastatin (MC:24.3;20;10 CC:24.7;20;10); rosuvastatin (MC: 12.7;
10;10 CC:13.1;10;10); and pravastatin (MC:37.6;40;40 CC:38.2;40;40). CONCLUSIONS:
This analysis suggests different statin use patterns by age, gender, and insurance.
Most frequently dispensed doses were 20 mg for simvastatin, 10 mg for atorvasta-
tin and rosuvastatin, and 40 mg for pravastatin.
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OBJECTIVES: To compare dosing patterns among patients in whom atorvastatin
(AS), simvastatin (SS), rosuvastatin (RS), or pravastatin (PS) was newly prescribed.
METHODS: Using a large US managed care database, study patients aged18 who
were newly prescribed AS, SS, RS, or PS between 10/01/2006-09/30/2007 were iden-
tified with a minimum 12 months pre- and 24 months post-index health plan
eligibility. A 6-month washout period free of use of any statin was applied to iden-
tify patients in whom statin therapy was newly prescribed. The index date was
defined as the date of the first prescription fill for statins and 4 cohortswere created
based on index statins: AS, SS, RS, or PS. Patients were followed up to 24 months
after the index date, and the average daily dose for 12 prescriptions per person,
average/median daily dose in each of the first 12 prescriptions, and the average
daily statin costs were compared among 4 cohorts. RESULTS: A total of 142,692
patientswere identified, comprised of 47,972 AS patients, 21,475 RS patients, 62,954
SS patients, and 10,291 PS patients. The average daily doses of all prescriptions
were 21.3mg for AS patients, 10.2mg for RS patients, 29.2mg for SS patients, and
34.6mg for PS patients. The average/median daily dose for the 1st and 12th pre-
scriptions were 20.8mg/20mg and 21.2mg/20mg for AS patients, 10.0mg/10mg and
10.5mg/10mg for RS patients, 28.4mg/20mg and 28.7mg/20mg for SS patients, and
32.8mg/40mg and 35.9mg/40mg for PS patients. The average daily statin costs for
the 1st and 12th prescriptions were $2.9 and $3.2 for AS patients, $2.7 and $3.1 for
RS patients, $1.5 and $0.8 for SS patients, and $1.4 and $0.9 for PS patients.
CONCLUSIONS: Patients initiating AS, RS, SS, and PS experienced little escalation
of their statin daily dosing over the 24-month follow-up period.
PCV90
FACTORS ASSOCIATED WITH SELECTIONS OF STATINS AMONG PATIENTS IN A
LARGE EMPLOYER-BASED CLAIMS DATABASE
Zhao Z1, Peng X1, Bae JP1, Sponseller CA2, LeNarz LA1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Kowa Pharmaceuticals America, Inc.,
Montgomery, AL, USA
A48 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
